The cell therapy company Kiadis Pharma BV started trading on the Euronext stock exchange in Amsterdam and Brussels on 2 July after an initial public offering that raised €32.7 million. At the opening, the shares traded at €12.50. This compares with an offer price of €11 to €13.75 per share.
